An Open Label, 26-Week Study Assessing Arbaclofen Placarbil Safety and Efficacy in Subjects With Spasticity Associated With Multiple Sclerosis With an Addendum Open-Label, 36-Week Study Assessing Arbaclofen Placarbil Safety in Subjects With Spasticity Associated With Multiple Sclerosis

Trial Profile

An Open Label, 26-Week Study Assessing Arbaclofen Placarbil Safety and Efficacy in Subjects With Spasticity Associated With Multiple Sclerosis With an Addendum Open-Label, 36-Week Study Assessing Arbaclofen Placarbil Safety in Subjects With Spasticity Associated With Multiple Sclerosis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2014

At a glance

  • Drugs Arbaclofen placarbil (Primary)
  • Indications Multiple sclerosis; Muscle spasticity
  • Focus Adverse reactions
  • Sponsors XenoPort
  • Most Recent Events

    • 14 Jul 2014 Planned primary completion date changed from 1 Dec 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 19 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 20 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top